New Antibiotic Designed To Overcome MRSA Bacteria
(1888PressRelease) A new topical antibiotic formulation, designed to overcome bacterial drug-
resistance, is now available Over The Counter (OTC). Known as Tetracycline-ABC, it kills the
most drug-resistant and deadly bacteria such as Staph, MRSA and Acinetobacter.
(1888PressRelease) An innovative drug design to combat antibiotics-resistant bacteria was
announced today by Phillips Company, a pharmaceutical manufacturer. The Tetracycline-ABC
antibiotic is an improvement over older antibiotics in this class due to a carrier formulation that
speeds the delivery of active ingredient deep into the cell structure of a wound. The unique
formulation uses both physical and chemical mechanisms of action to kill bacteria. Most existing
antibiotics use only a chemical mechanism for effectiveness, resulting in those drugs becoming
less effective over time as bacteria evolve to become able to survive the effects of antibiotics.
This new physical approach uses an antibiotic formulation designed to enhance physical
transport and physical cell penetration. The result is that the active ingredient is rapidly
transported deep into a wound where the chemical mechanism of action can be more effective.
The new antibiotic formulation is based on tetracycline, the world's most-used broad-spectrum
antibiotic, according to Steve Keough, spokesman for Phillips Company.
In-vitro tests, in controlled laboratory conditions, have shown that the Zone of Inhibition or kill
zone is significantly larger than the area where the product is applied. Keough further added,
"Tetracycline-ABC topical antibiotic is clearly a best-in-class pharmaceutical solution, with
applications across multiple fields of use." This new antibiotic formulation acts rapidly - usually
within 24 to 36 hours - as compared to most other antibiotics that require several days of
treatment for best results.
Methicillin Resistant Staphylococcus Aureus (MRSA), the most notorious antibiotic-resistant
strain of staph bacteria, has been wreaking havoc throughout communities all over the world.
According to the United States Centers for Disease Control, more people in the United States are
dying of MRSA infections than because of AIDS; raising MRSA infection to epidemic
proportions. To make matters even worse, some experts are now predicting an emergence of new
strains of antibiotic-resistant bacteria in the future.
It is becoming more common for bacteria to develop drug resistance to a chemical kill
mechanism. Drug developers believe it takes much longer for bacteria to develop drug resistance
to a physical kill mechanism. This is because it is relatively easy for bacteria to change their
chemistry, but it takes numerous generations for bacteria to grow a new kind of cell wall
"Our novel approach to overcome drug resistance of antibiotics is designed to sustain the
effectiveness of antibiotics and other topical drugs for many years," said Howard Phillips, the
General Manager of Phillips Company. "This gives new topical drug products a longer useful
lifetime and therefore more commercial value. This technology, when licensed to larger
pharmaceutical companies, may provide stronger incentive for the discovery and development of
new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to
the uncertain new-drug commercial lifetime which is diminished when bacteria develop
immunity to that drug," according to Phillips.
The new drug formulation was carefully tested on ten of the most harmful kinds of bacteria and
it was found to be the most effective against MRSA. The Tetracycline-ABC topical antibiotic
kills all other harmful Gram positive and Gram negative bacteria that have been available for
testing. Phillips Company believes this is the world's strongest broad-spectrum topical
antibiotic. Tetracycline-ABC kills the most drug-resistant and the most deadly bacteria (Staph,
MRSA and Acinetobacter), which cause community or hospital acquired infections.
Phillips Company is a pharmaceutical development company with manufacturing capacity of
50,000 units per month. Using the develop-and-license business model, the company licensed
six pharmaceutical products in 2010. Tetracycline-ABC will likely be licensed to a larger
company for manufacturing and commercialization in both OTC and prescription drug
Check out http://www.PhillipsCompany.4T.com for more details and information.